Released: April 5, 2023
Expires: April 5, 2024
An interactive and patient-centric CE learning experience, including discussion of patient cases depicting clinical challenges associated with the personalized treatment of multiple sclerosis (MS).
Neurologists, advanced practice clinicians, nurses, pharmacists, and other clinicians who are part of the team that manages patients with MS.
This activity is supported by independent educational grants from Biogen and Genentech.
At the conclusion of this activity, participants should be better able to:
- Examine patient-specific considerations that affect treatment decisions for patients with MS
- Review disease-modifying and symptomatic therapies for MS
- Recognize the socio-economic and ethnocultural considerations and integrate strategies to address these barriers into the care of people living with MS
- With input from appropriate members of the health care team, develop personalized treatment plans for the care of persons with MS that integrate key learnings from current evidence in order to address individual patient characteristics
In support of improving patient care, this activity has been planned and implemented by The Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.
The CMSC designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The CMSC designates this activity for a maximum of 1.00 NCPD credit (1.00 in the area of pharmacology).
This knowledge-based activity, UAN JA4008165-9999-23-007-H01-P, qualifies for 1.00 contact hour (0.10 CEUs) of continuing pharmacy education credit.
Interprofessional Continuing Education
This activity was planned by and for the health care team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
Disclosure of Financial Relationships
In accordance with the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Continuing Education, CMSC and Catamount Medical Education require that individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies. CMSC and Catamount Medical Education mitigate all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, CMSC and Catamount Medical Education seek to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC and Catamount Medical Education are committed to providing learners with high-quality CE activities that promote improvements in health care and not those of a commercial interest.
James Bowen, MD
Multiple Sclerosis Center
Swedish Neuroscience Institute
Dr. Bowen discloses the following:
Consultant: Biogen IDEC, Bristol-Myers Squibb, EMD Serono Inc., Genentech, Novartis Pharmaceuticals Corporation, TG Therapeutics
Speakers Bureau: Biogen IDEC, Bristol-Myers Squibb, EMD Serono Inc., Genentech, Novartis Pharmaceuticals Corporation
Contracted Research: Biogen IDEC, Bristol-Myers Squibb, Genentech, Genzyme, Novartis Pharmaceuticals Corporation, Roche, TG Therapeutics
Ownership Interest: Amgen
Activity Staff Disclosures
June Halper, MSN, APN-C, MSCN, FAAN, and Laurie Scudder, DNP, NP, served as planners and reviewers and have disclosed no relevant financial relationships.
All other planners, reviewers, staff, or other members of the Continuing Professional Education Committee at The Consortium of Multiple Sclerosis Centers who control content have disclosed no relevant financial relationships.
The planners, reviewers, editors, staff, CE committee, or other members at Catamount Medical Education who control content have disclosed no relevant financial relationships.
Disclosure of Unlabeled Use
CMSC and Catamount Medical Education require CE faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.